Literature DB >> 33060032

Guidelines of the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL), part I: Primary treatment of pleomorphic adenoma.

S Vergez1, N Fakhry2, C Cartier3, T Kennel3, M Courtade-Saidi4, E Uro-Coste4, A Varoquaux5, C-A Righini6, O Malard7, P Mogultay3, J Thariat8, S Tronche9, R Garrel3, D Chevalier10.   

Abstract

INTRODUCTION: The authors present the guidelines of the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL) for the diagnosis and treatment of pleomorphic adenoma (PA) of the salivary glands.
METHOD: A review of the literature was performed by a multidisciplinary task force. Guidelines were drafted based on the articles retrieved and the workgroup members' individual experience. Guidelines were graded A, B, C or expert opinion by decreasing level of evidence.
RESULTS: In clinically suspected salivary gland PA, MRI should be performed, including head and neck lymph node levels. Fine needle aspiration cytology is particularly recommended for tumours difficult to characterise by MRI. Frozen section biopsy should be performed to confirm diagnosis and adapt the surgical procedure in case of intraoperative findings of malignancy. Complete resection of the parotid PA should be performed en bloc, including margins, when feasible according to tumour location, while respecting the facial nerve. Enucleation (resection only in contact with the tumour) is not recommended. For the accessory salivary and submandibular glands, complete en bloc resection should be performed.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Parotid; Pleomorphic adenoma; Salivary glands; Submandibular gland

Mesh:

Year:  2020        PMID: 33060032     DOI: 10.1016/j.anorl.2020.09.002

Source DB:  PubMed          Journal:  Eur Ann Otorhinolaryngol Head Neck Dis        ISSN: 1879-7296            Impact factor:   2.080


  1 in total

Review 1.  Reporting quality of clinical practice guidelines on head and neck cancer: a systematic review.

Authors:  Jiabao Hou; Qiangqiang Guo; Hanqiong Zhou; Xuan Wu; Lidan Hao; Zhe Zhang; Shuxiang Ma; Jing Han; Zhen He; Zhensheng Liu; Yaolong Chen; Qiming Wang
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.